Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD


Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Related Videos
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.